“Our goal is to address the unmet and underserved needs of patients and health care professionals in the dermatology market,” said Robert J. Bitterman, Sr., President and Chief Executive Officer of CLS. “Undesired skin conditions can impact a person’s health, appearance and self-esteem. Medications which are safe, effective, convenient and affordable are needed to better manage and control various disorders so patients will not be troubled by the psychological burdens of these conditions.”

CLS management has an experienced team well-versed in the development and commercialization of dermatologic therapies, validated by a long history of successful product launches in the U.S. Over the past few decades, CLS professionals have played a critical role in securing U.S. Food and Drug Administration (FDA) clearance leading to the introduction of numerous new, highly recognized pharmaceuticals and medical devices.

Maura Flynn, President, 2015-2016 of the Dermatology Nurses Association, stated: “The DNA welcomes a forward-thinking organization like Cutanea Life Sciences whose expertise, innovation and commitment will bring value to their efforts to provide quality care. Promoting excellence in dermatologic care is the core purpose of our organization.”

Rosacea is one of the more difficult skin disorders to manage and control. “The estimated 16 million Americans who live with rosacea will always benefit from education, information and hopefully improved treatments to manage this widespread but poorly understood skin disorder,” said Samuel Huff, Executive Director of the National Rosacea Society. “I am pleased that Cutanea Life Sciences is addressing these needs.”

.@CutaneaDerm is changing the way you think about a valued #dermatology partner Tweet

About Cutanea Life Sciences

Cutanea Life Sciences, Inc., headquartered in Wayne, PA, is a specialty pharmaceutical company whose mission is to develop innovative technologies, optimizing intellectual property and therapeutic applications culminating in market leading products to treat diseases and disorders of the skin and related tissue. CLS seeks to improve human health and appearance, and create value for patients and medical professionals by satisfying unmet and underserved medical needs. CLS is a wholly-owned subsidiary of the Osaka-based Maruho Co., Ltd., a leading dermatology company in Japan that celebrated its 100^th anniversary in 2015.

CLS is pursuing therapies for the treatment of acne, rosacea, psoriasis, atopic dermatitis, and various forms of warts caused by human papillomavirus (HPV). It also has a novel soft tissue augmentation agent in early development. CLS intends to direct these products through the required regulatory pathway and, upon FDA clearance, commercialize them directly through a CLS sales force and commercial infrastructure that will focus primarily on dermatology medical practices.

For more information, visit www.cutanea.com and follow CLS on Facebook, Twitter, LinkedIn and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from CLS’s current expectations. CLS’s expectations and, therefore, any forward-looking statements in this press release could be affected by risks and uncertainties relating to a number of factors, including the following: the success, cost and timing of CLS’s product development activities, studies and clinical trials; the success of competing products that are or become available; CLS’s ability to commercialize its product candidates; the size and growth potential of the markets for CLS’s product candidates, and CLS’s ability to service those markets; CLS’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of CLS’s product candidates; and CLS’s expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates. Any forward-looking statements that CLS makes in this press release speak only as of the date of this press release. CLS assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Media Contacts:
Karen Dombek
MCS Healthcare Public Relations
(800) 477-9626
[email protected]

Andy Hachadorian
Cutanea Life Sciences
(484) 568-4323
[email protected]